Inflammation and Cellular Immunity in Vaginal Tissue in Patients With Pelvic Organ Prolapse
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03748693|
Recruitment Status : Not yet recruiting
First Posted : November 21, 2018
Last Update Posted : November 21, 2018
The aim of this study is to investigate the inflammatory and maturation processes of immature myeloid cells (IMC) in the vaginal tissue in women with advanced pelvic organ prolapse (POP) (stage III-IV) and in normal non-POP controls.
We hypothesize that the processes contributing to POP may be related to immune response and changes in myeloid cell populations and the cytokine environment.
|Condition or disease||Intervention/treatment|
|Pelvic Organ Prolapse||Procedure: Hysterectomy Procedure: Colporrhaphy|
|Study Type :||Observational|
|Estimated Enrollment :||20 participants|
|Official Title:||Inflammation and Cellular Immunity in Vaginal Tissue in Patients With Pelvic Organ Prolapse|
|Estimated Study Start Date :||December 2018|
|Estimated Primary Completion Date :||September 2019|
|Estimated Study Completion Date :||September 2019|
Women with POP undergoing surgery in our OB/GYN department.
Surgery performed on women with POP
Women undergoing hysterectomy for other indications.
Surgery performed on women with a variety of gynecological indications
- Immune response in POP [ Time Frame: Two weeks ]Tissue biopsy will analyzed for IMC and compared to control group
- Cytokine environment in POP [ Time Frame: Two weeks ]Tissue biopsy will analyzed for cytokine environment and compared to control group
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03748693
|Contact: Mariana Ordonez, MDemail@example.com|